Testing Enarodustat for Anemia in Chronic Kidney Disease Not on Dialysis
Compares two hemoglobin targets with enarodustat in adults with anemia from kidney disease.
Plain-language title generated from the registry record
Registry title: Correction of Anemia With Enarodustat in Non-dialysis Dependent Chronic Kidney Disease
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18-75 with anemia caused by chronic kidney disease who are not on dialysis. It tests enarodustat at two different hemoglobin targets.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Chronic kidney disease stages 2-5 (10 ≤ eGFR < 90 mL/min/1.73m2), not dependent on dialysis, with anemia from kidney disease. Hemoglobin 6-10 g/dL if no recent ESA or HIF-PHI treatment, or 8-12 g/dL if currently on ESA (≤ 10,000 IU/week) or roxadustat (≤ 100 mg TIW).
- Earlier treatment
- People not treated with ESA or HIF-PHI in the last 6 weeks, or people currently on ESA or roxadustat within the stated doses, can join. Blood transfusion in the last 2 months and immunosuppressants in the last 6 months are not allowed.
- Biomarker or test result
- Serum ferritin above 100 μg/L or transferrin saturation above 20%. Body weight 45 to 100 kg (99–220 lb).
Main reasons for not taking part
- Uncontrolled high blood pressure or very high protein in the urine
- Anemia from causes other than kidney disease
- Serious blood clot or heart event, or severe heart failure (NYHA class IV), in the last 6 months
- Active tumor, severe infection, or severe liver problems
- Pregnant or breastfeeding women
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT06725810, who can take part
Where in China
- Zhongshan Hospital,Fudan UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Zhongshan Hospital
- Trial code
- NCT06725810
- Record updated
- 28 July 2025
- Original description
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group （hemoglobin of 13 g/dl）and low-hemoglobin target group （hemoglobin of 11 g/dl）and administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.Read full original descriptionShow less
A Prospective, Open-label, Randomized, Multicenter Study on the Rational Hemoglobin Target Value in Patients With Anemia of Non-dialysis Chronic Kidney Disease Treated With Enarodustat
The CANNON trial is a prospective, open-label, randomized, multicenter study designed to investigate rational hemoglobin target value in patients with anemia of non-dialysis chronic kidney disease treated with enarodustat. Eligible patients are randomly assigned 1:1 to the high-hemoglobin target group （hemoglobin of 13 g/dl）and low-hemoglobin target group （hemoglobin of 11 g/dl）and administered with enarodustat to achieve and maintain target hemoglobin over 96 weeks. The first primary endpoint was the difference of mean change in 36-Item Short Form Health Survey at week 24. The second primary endpoint was safety endpoints included time to major adverse cardiovascular + event (MACE+; all-cause mortality, myocardial infarction, stroke, and congestive heart failure requiring hospitalization) during 96 weeks.
Inclusion: Aged 18-75 years at the time of consent to participate; Body weight ranged from 45 to 100 kg; Diagnosed with CKD stages 2-5 (10 ≤ eGFR < 90 mL/min/1.73m2) and were not dialysis dependent; Diagnosed with renal anemia:; 1)Hemoglobin level of 6 - 10 g/dL for those who have not received ESA or HIF-PHI treatment within 6 weeks at screening; 2)Hemoglobin level of 8 - 12 g/dL for those who are currently receiving ESA (ESA dosage ≤ 10,000 IU/week) or HIF-PHI (roxadustat dosage≤ 100 mg TIW) at screening; 5. Serum ferritin > 100 μg/L or transferrin saturation > 20% at screening; 6. Voluntary participation in the trial and signing of the informed consent form.
Exclusion: Uncontrolled hypertension identified as systolic blood pressure >160mmHg or diastolic blood pressure >100mmHg after 4 weeks of regular and adequate drug therapy prior to screening; History of active bleeding within 4 weeks prior to screening; History of serious thrombotic event such as a myocardial infarction, cerebral infarction, pulmonary embolism, unstable angina, or PCI or cardiac surgery within 6 months prior to screening; History of blood transfusion within 2 months prior to screening; History of usage of immunosuppressants or other immune therapies within 6 months prior to screening; Patients who are estimated to require dialysis, kidney transplantation, or major surgery within 6 months; Receiving ESA combined with roxadustat treatment at screening; Anemia due to other reasons except CKD including systemic hematological disorders (such as myelodysplastic syndrome, aplastic anemia, etc.), hemolytic anemia, hemorrhagic anemia or cancer-related anemia; History of autoimmune diseases which could result in anemia such as systemic lupus erythematosus and ANCA vasculitis; Severe heart failure (NYHA class IV) at screening; History of proliferative retinopathy or diabetic retinopathy requiring ophthalmological treatment; Severe active infections (such as active tuberculosis, fungal infections, etc.); Patients who are bedridden or have difficulty walking, or have a history of atrial fibrillation or deep vein thrombosis of the lower limbs; History of active tumors; Patients with a history of severe drug allergies (such as anaphylactic shock), or known allergies to any of the active ingredients or excipients of enarodostat; Severe liver and biliary system complications (AST or ALT >3 times the upper limit of normal, total bilirubin >2 times the upper limit of normal) at screening; Uncontrolled proteinuria identified as UACR >3000mg/g or 24-hour urine protein >3.5g in non-diabetic patients and UACR of >5000mg/g or 24-hour urine protein >5.5g in diabetic patients; Severe hyperparathyroidism (iPTH ≥ 500 pg/mL); Female patients who are pregnant or breastfeeding, or non-childbearing women who do not agree to effective contraception; Patients who are currently participating in any other interventional clinical trial; Other reasons determined by the investigator not suitable for participation in the study.